Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNBN
Period2017-01-01 → 2017-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100CP6F.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥229m2017-01-01 → 2017-12-31StandaloneNet sales
Revenue¥178m2016-01-01 → 2016-12-31StandaloneNet sales
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Revenue¥29m2014-01-01 → 2014-12-31dStandaloneNet sales (5-year summary)
Revenue¥1m2013-01-01 → 2013-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOperating income
Operating income−¥861m2016-01-01 → 2016-12-31StandaloneOperating income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOrdinary income
Ordinary income−¥864m2016-01-01 → 2016-12-31StandaloneOrdinary income
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥726m2014-01-01 → 2014-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥625m2013-01-01 → 2013-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.1bn2017-01-01 → 2017-12-31StandaloneIncome before income taxes
Profit before tax−¥928m2016-01-01 → 2016-12-31StandaloneIncome before income taxes
Net income−¥1.1bn2017-01-01 → 2017-12-31StandaloneProfit loss
Net income−¥931m2016-01-01 → 2016-12-31StandaloneProfit loss
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Net income−¥739m2014-01-01 → 2014-12-31dStandaloneNet income loss (5-year summary)
Net income−¥636m2013-01-01 → 2013-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.5bnat 2017-12-31StandaloneAssets
Total assets¥3.1bnat 2016-12-31StandaloneAssets
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.0bnat 2014-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.7bnat 2013-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥594mat 2017-12-31StandaloneLiabilities
Total liabilities¥523mat 2016-12-31StandaloneLiabilities
Net assets / equity¥2.9bnat 2017-12-31StandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets
Net assets / equity¥4.4bnat 2014-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥5.1bnat 2013-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.9bnat 2017-12-31StandaloneCash and deposits
Cash and deposits¥2.6bnat 2016-12-31StandaloneCash and deposits
Cash & equivalents¥1.9bnat 2017-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2014-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥5.4bnat 2013-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥903m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥814m2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥599m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥257m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥110m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥6m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥233,0002014-01-01 → 2014-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥5.4bn2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-80.552014-01-01 → 2014-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-94.332013-01-01 → 2013-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥263.54at 2017-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥476.03at 2014-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥561.17at 2013-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio82.9%at 2017-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2014-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio89.3%at 2013-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued11,086,000at 2017-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,200at 2014-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,076,900at 2013-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees29at 2017-12-31StandaloneNumber of employees
Employees30at 2016-12-31StandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees
Employees28at 2014-12-31dStandaloneNumber of employees
Employees22at 2013-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 24
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2017-01-01 → 2017-12-31¥1m
Reconciling Itemsreconcilingsegment profit2017-01-01 → 2017-12-31−¥537m
Diagnostic Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥104m
Pharmaceutical Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥438m
Total Of Reportable Segments And Otherssegment totalrevenue2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalrevenue external2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalsegment profit2017-01-01 → 2017-12-31−¥542m
Reconciling Itemsreconcilingdepreciation2016-01-01 → 2016-12-31¥4m
Reconciling Itemsreconcilingsegment profit2016-01-01 → 2016-12-31−¥438m
Diagnostic Divisionreportable segmentdepreciation2016-01-01 → 2016-12-31¥11m
Diagnostic Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥105m
Pharmaceutical Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥318m
Total Of Reportable Segments And Otherssegment totaldepreciation2016-01-01 → 2016-12-31¥11m
Total Of Reportable Segments And Otherssegment totalrevenue2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalrevenue external2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalsegment profit2016-01-01 → 2016-12-31−¥423m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 712
ItemContextValueUnit
Increase decrease in provision for retirement benefits ope cfCurrentYearDuration_NonConsolidatedMember928000JPY
Interest and dividends income ope cfPrior1YearDuration_NonConsolidatedMember-4898000JPY
Interest and dividends income ope cfCurrentYearDuration_NonConsolidatedMember-3891000JPY
Interest expenses ope cfPrior1YearDuration_NonConsolidatedMember3221000JPY
Interest expenses ope cfCurrentYearDuration_NonConsolidatedMember3274000JPY
Foreign exchange losses gains ope cfPrior1YearDuration_NonConsolidatedMember885000JPY
Foreign exchange losses gains ope cfCurrentYearDuration_NonConsolidatedMember7864000JPY
Loss gain on money held in trust ope cfbnkPrior1YearDuration_NonConsolidatedMember1408000JPY
Loss gain on money held in trust ope cfbnkCurrentYearDuration_NonConsolidatedMember－JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YearDuration_NonConsolidatedMember-65228000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYearDuration_NonConsolidatedMember-22385000JPY
Decrease increase in inventories ope cfPrior1YearDuration_NonConsolidatedMember592000JPY
Decrease increase in inventories ope cfCurrentYearDuration_NonConsolidatedMember-3463000JPY
Decrease increase in accounts receivable other ope cfPrior1YearDuration_NonConsolidatedMember188000JPY
Decrease increase in accounts receivable other ope cfCurrentYearDuration_NonConsolidatedMember-500000JPY
Decrease increase in advance payment ope cfPrior1YearDuration_NonConsolidatedMember-43262000JPY
Decrease increase in advance payment ope cfCurrentYearDuration_NonConsolidatedMember39910000JPY
Increase decrease in accounts payable other ope cfPrior1YearDuration_NonConsolidatedMember45836000JPY
Increase decrease in accounts payable other ope cfCurrentYearDuration_NonConsolidatedMember-1061000JPY
Other net ope cfPrior1YearDuration_NonConsolidatedMember10039000JPY
Other net ope cfCurrentYearDuration_NonConsolidatedMember-26137000JPY
Subtotal ope cfPrior1YearDuration_NonConsolidatedMember-899750000JPY
Subtotal ope cfCurrentYearDuration_NonConsolidatedMember-1091485000JPY
Interest and dividends income received ope cf inv cfPrior1YearDuration_NonConsolidatedMember1703000JPY
Interest and dividends income received ope cf inv cfCurrentYearDuration_NonConsolidatedMember1004000JPY
Interest expenses paid ope cf fin cfPrior1YearDuration_NonConsolidatedMember-3261000JPY
Interest expenses paid ope cf fin cfCurrentYearDuration_NonConsolidatedMember-3154000JPY
Income taxes paid ope cfPrior1YearDuration_NonConsolidatedMember-2115000JPY
Income taxes paid ope cfCurrentYearDuration_NonConsolidatedMember-3205000JPY
Net cash provided by used in operating activitiesPrior1YearDuration_NonConsolidatedMember-903424000JPY
Net cash provided by used in operating activitiesCurrentYearDuration_NonConsolidatedMember-1096840000JPY
Payments into time deposits inv cfPrior1YearDuration_NonConsolidatedMember-18000JPY
Payments into time deposits inv cfCurrentYearDuration_NonConsolidatedMember-400006000JPY
Proceeds from withdrawal of time deposits inv cfPrior1YearDuration_NonConsolidatedMember400000000JPY
Proceeds from withdrawal of time deposits inv cfCurrentYearDuration_NonConsolidatedMember600000000JPY
Purchase of money held in trust inv cfPrior1YearDuration_NonConsolidatedMember-400000000JPY
Purchase of money held in trust inv cfCurrentYearDuration_NonConsolidatedMember－JPY
Proceeds from cancellation of money held in trust inv cfPrior1YearDuration_NonConsolidatedMember398591000JPY
Proceeds from cancellation of money held in trust inv cfCurrentYearDuration_NonConsolidatedMember－JPY
Purchase of property plant and equipment inv cfPrior1YearDuration_NonConsolidatedMember-20994000JPY
Purchase of property plant and equipment inv cfCurrentYearDuration_NonConsolidatedMember-1436000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YearDuration_NonConsolidatedMember913000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYearDuration_NonConsolidatedMember－JPY
Purchase of investment securities inv cfPrior1YearDuration_NonConsolidatedMember-112620000JPY
Purchase of investment securities inv cfCurrentYearDuration_NonConsolidatedMember-55670000JPY
Purchase of stocks of subsidiaries and affiliates inv cfPrior1YearDuration_NonConsolidatedMember-10173000JPY
Purchase of stocks of subsidiaries and affiliates inv cfCurrentYearDuration_NonConsolidatedMember－JPY
Payments of long term loans receivable inv cfPrior1YearDuration_NonConsolidatedMember－JPY
Payments of long term loans receivable inv cfCurrentYearDuration_NonConsolidatedMember-11079000JPY
Payments for lease and guarantee deposits inv cfPrior1YearDuration_NonConsolidatedMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2016-12-31pass rounding
balance sheet identitynon_consolidated 2017-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2015-12-31pass
statement vs summary · net assetsnon_consolidated 2016-12-31pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · operating cash flownon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · operating cash flownon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · revenuenon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · revenuenon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · total assetsnon_consolidated 2016-12-31pass
statement vs summary · total assetsnon_consolidated 2017-12-31pass